SANTA MONICA, Calif., Nov. 10, 2016 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (OTCQB:OPNT), a specialty pharmaceutical company developing pharmacological treatments for substance use, addictive and eating disorders, announced the appointment of Thomas T. Thomas, CFA, to the company's Board of Directors. Mr. Thomas worked at Genentech, Inc. for more than twelve years, culminating as the company's Corporate Treasurer. His responsibilities included treasury operations, cash and investment management, corporate finance, global procurement, enterprise risk management, business continuity, and real estate. "With his valuable background, we welcome Thomas T. Thomas to our Board of Directors," said Roger Crystal, M.D., Chief Executive Officer of Opiant. "We consider his experience at Genentech to be a great asset to Opiant." "There's an unmet need for new addiction treatments and Opiant's compelling approach could have a transformative impact on patients and their families," Mr. Thomas said. "Opiant could make significant contributions to the field of addiction medicine." "With NARCAN® Nasal Spray now approved by the FDA and widely available to treat opioid overdoses, via our partner Adapt Pharma, we are focused on advancing our pipeline and Mr. Thomas has the financial experience to help Opiant achieve this," said Dr. Crystal. Mr. Thomas currently serves as a board member at the Cancer Prevention Institute of California. After his career at Genentech, Mr. Thomas served as Chief Financial Officer and Interim Chief Executive Officer at Stupski Foundation, an organization working to transform the public school system. He has also served in financial roles at Del Monte Foods, Inc. and GE Capital. Mr. Thomas is a Chartered Financial Analyst and has a master's degree in business administration from the University of Cincinnati. "Opiant is aggressively addressing a serious public health issue with its nasal opioid antagonist technology in NARCAN®," Mr. Thomas said. "As I join Opiant's board, I look forward to using my corporate financial experience to help the company advance its pipeline and business operations, and bring forward new and innovative therapies that improve patient's lives, while continuing to build Opiant's shareholder value."
The ex-dividend date for OPNET Technologies (Nasdaq:OPNT) is tomorrow, June 12, 2012. Owners of shares as of market close today will be eligible for a dividend of 15 cents per share. At a price of $26.02 as of 10:09 a.m., the dividend yield is 2.3%.
Shares of OPNET Technologies (Nasdaq:OPNT) have taken a tremendous swing upward. The stock is trading at $26.68 as of 9:40 a.m. ET, 20.7% above Monday's closing price of $22.11. Volume is at 143,778, 0.6 times the daily average of 238,600.